This statistic was assembled from several editions of Novartis' annual report. * With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015. ** During this year, eye care division Alcon was spun off and became an own company. Thus...
The section "—Goodwill and intangible assets other than goodwill" in Note 1 to the Consolidated Financial Statements in the Annual Report 2023 provides additional information on key assump- tions that are highly sensitive in the estimation of fair val- ues using valuation techniques. Transaction ...
Review Report. Available at: http://www.pmda.go.jp/files/000216877.pdf. Last accessed November 2017. [17] US Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2016. [18] Dean LE et al. Global prevalence...
Real-Life Analysis of CML Management Demonstrates that Second-Line Therapy is Frequently Used But is Prematurely Discontinued For Intolerance: Report on Behalf of the CML-MPN Quebec Research Group. Poster presented at: EHA Annual Meeting; June 13, 2015. Hughes ...
Everything on "Novartis" in one document: edited and divided into chapters, including detailed references. Go to report Statista is a great source of knowledge, and pretty helpful to manage the daily work. Christof Baron CEO, MindShare Germany Statistics on " Novartis " Overview Financials Seg...